HEPATOCELLULAR CARCINOMA

This adverse event was reported 7612 times

These drugs are most commonly taken by patients reporting HEPATOCELLULAR CARCINOMA:

# Drug Count
0 SORAFENIB 1899
1 RIBAVIRIN 967
2 SOFOSBUVIR 911
3 ATEZOLIZUMAB 826
4 BEVACIZUMAB 809
5 REGORAFENIB 488
6 LEDIPASVIR AND SOFOSBUVIR 402
7 TACROLIMUS 307
8 CABOZANTINIB 264
9 TACROLIMUS EXTENDED-RELEASE CAPSULES 255
See all common drugs associated with HEPATOCELLULAR CARCINOMA

HEPATOCELLULAR CARCINOMA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SORAFENIB 1899 0.0917
1 NITISINONE 61 0.0638
2 SOFOSBUVIR 911 0.0464
3 REGORAFENIB 488 0.0420
4 ADEFOVIR DIPIVOXIL 34 0.0268
5 LEDIPASVIR AND SOFOSBUVIR 402 0.0210
6 ATEZOLIZUMAB 826 0.0208
7 SOFOSBUVIR, VELPATASVIR, AND VOXILAPREVIR 22 0.0203
8 ENTECAVIR 216 0.0183
9 RIBAVIRIN 967 0.0151
See all drugs enriched for association with HEPATOCELLULAR CARCINOMA